(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer — which accounts for 80-90 per cent of cases — can safely take HRT during or after their treatment.
Related Topics
The Overview: June 2026
Nearly 500 people have already registered for OCRA’s International Gynecologic Cancer Conference®—the largest conference dedicated to the gynecologic cancer community—taking place on September 16–17. The conference is free, online, and open to all, and will include programming for ovarian, endometrial, cervical, and rare gynecologic cancers. For the first time, each of these diseases will have a dedicated Ask the Experts session. Learn … Continued
Inside the Think Tank: Stopping Ovarian Cancer Before it Starts
On June 1–2, the Ovarian Cancer Observatory—part of OCRA’s broader investment in research initiatives—convened its first in-person Forum in Vancouver. Roughly 50 of the field’s brightest clinicians, pathologists, and epidemiologists gathered for what became, in essence, a two-day think tank on preventing ovarian cancer. The Observatory is funded through a grant from OCRA and was … Continued
OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
